[Posterior reversible encephalopathy syndrome during nilotinib treatment for chronic myeloid leukemia].
Rinsho Ketsueki
; 64(12): 1514-1518, 2023.
Article
in Ja
| MEDLINE
| ID: mdl-38220151
ABSTRACT
Here we present the case of a 50-year-old woman with chronic myeloid leukemia who received nilotinib as initial treatment. After about 2 years of nilotinib therapy, she developed headache, blurred vision, impaired consciousness, and marked hypertension. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and was strongly suspected to be a vascular adverse event caused by nilotinib. Nilotinib was withheld and the patient was treated with antihypertensive drugs under ventilator management. Her symptoms resolved quickly. The most likely cause of PRES is systemic arterial hypertension and endothelial dysfunction due to direct injury leading to dysfunction at the level of the blood-brain barrier, along with the resultant vasogenic edema. PRES has been reported with some tyrosine kinase inhibitors, but this is the first case of PRES during nilotinib treatment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Leukemia, Myeloid
/
Posterior Leukoencephalopathy Syndrome
/
Hypertension
Limits:
Female
/
Humans
/
Middle aged
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2023
Type:
Article